Switching studies intended to support interchangeability should include as least three transitions between a biosimilar and its US-licensed reference product, FDA’s new draft guidance on interchangeability states.
Such studies also should include a comparator arm in which patients receive only the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?